Immunovant, Inc. IMVT Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s common stock, shares authorized (in shares)?
- Immunovant, Inc. (IMVT) reported common stock, shares authorized (in shares) of $500M in Q4 2025.
- How has Immunovant, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Immunovant, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
- What is the long-term trend for Immunovant, Inc.'s common stock, shares authorized (in shares)?
- Over 4 years (2021 to 2025), Immunovant, Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $500M to $500M.